EVUSHELD REFERRAL FORM



PATIENT INFORMATION				PRESCRIBER INFORMATION		
Last Name	First Name		DOB	Name of Contact Sending Referral Title		
Gender	Social Security #		Primary Language	Preferred Contact □ Email Referral Contact Email Method (check one) □ Phone □ Fax		
Address				Office Phone Office Fax		
City State		ZIP	Practice / Facility Name			
Allergies				Address		
Phone	Height		Weight	City State ZIP		
ICD-10 Code □ Code Qualifying diagnosis □ U09.9 Post-Covid condition unspecified				Prescriber Name / Specialty		
INSURANCE INFOR	MATION					
Insurance Provider			Plan ID #	Eligible for Medicare		
Insured's Name			Relationship to Patient	If no insurance, list driver's license number and state of issue		
Please fax with order form: Current Medication List & Copy of Insurance Card						
				<u> </u>		
ELIGIBILITY				MEDICATION ORDERS		
Exclusion Criteria: EVUSHELD is not authorized for use in individuals: For treatment of COVID-19 For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2 Pre-exposure prophylaxis with EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination. In individuals who have received a COVID-19 vaccine, EVUSHELD should be administrated at least two weeks of the vaccination.				*EVUSHELD may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which EVUSHELD belongs (i.e., antiinfectives) Standing orders may not be used per the EUA.		
				*EVUSHELD New One Time Dose: EVUSHELD once 300mg tixagevimab IM and 300mg cilgavimab IM as separate IM injections		
administered at least two weeks after vaccination. Inclusion Criteria: Check all that apply For the pre-exposure prophylaxis of COVID-19 in adults and p years of age and older weighing at least 40 kg):			s and pediatric individuals (12	*EVUSHELD Previous 150mg/150mg Dose: Additional EVUSHELD one time 150mg tixagevimab IM and 150mg cilgavimab IM as separate IM injections. If patient has received 150mg equal to or less than 90 days previously they shou receive an additional 150mg/150mg dose		
Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARSCoV-2 and:				Anaphylaxis Kit per Amber Specialty Pharmacy Home Infusion anaphylaxis treatment protocol.		
Who have moderate to severe immune compromise due to a medical condition such as cancer, untreated HIV, etc (not a complete list, see EUA for more)				Indicate vaccination status:		
Who receive immunosuppressive medications or trea an adequate immune response to COVID-19 vaccinations.				☐Unvaccinated ☐Partially Vaccinated ☐Fully Vaccinated ☐Boosted		

Nursing Orders	SIGNATURE	
Administer IM in two injections, Monitor patient for one hour post injection, follow Anaphylaxis protocol if necessary.	Prescriber Signature	Date
Phone: 855.896.9254 Fax: 855.370.0086	Please Print Name	